Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Pharmacokinetics
55%
Efavirenz
38%
Rifapentine
34%
Tenofovir Disoproxil
27%
Rifampicin
25%
Emtricitabine
25%
Tenofovir
23%
Dolutegravir
21%
Tenofovir Alafenamide
19%
Darunavir
15%
Lopinavir Plus Ritonavir
14%
Rilpivirine
14%
Pharmacodynamics
14%
Rifamycin
13%
Ritonavir
13%
Raltegravir
13%
Isoniazid
12%
Lamivudine
12%
Integrase
11%
Rifabutin
11%
Nevirapine
11%
Levonorgestrel
10%
SARS Coronavirus
10%
Clinical Trial
10%
Human Immunodeficiency Virus Infection
9%
Disease
9%
Bioavailability
9%
Human Immunodeficiency Virus 1
8%
Tuberculostatic Agent
8%
Mouse
8%
Abacavir
8%
Integrase Inhibitor
7%
Blood-Brain Barrier
7%
Pharmacokinetic Modeling
7%
Etravirine
7%
Adverse Event
7%
Cabotegravir
6%
HIV Associated Dementia
6%
Prodrug
6%
Combination Therapy
6%
Bagg Albino Mouse
6%
Moxifloxacin
6%
Infection
6%
Cobicistat
6%
Elvitegravir
6%
Bictegravir
5%
Antibiotic Agent
5%
Subcutaneous Injection
5%
Small Interfering RNA
5%
Keyphrases
Rifapentine
21%
Antiretroviral Therapy
20%
Tenofovir Alafenamide
18%
Pharmacokinetics
17%
Integrase Strand Transfer Inhibitor (INSTI)
14%
Antiviral Drugs
14%
HIV Patients
14%
Tenofovir Disoproxil Fumarate
14%
AIDS/HIV
13%
Efavirenz
12%
Lymphoid Tissue
12%
Emtricitabine
11%
Antiretroviral
10%
Nevirapine
10%
Cell-Associated
10%
Human Immunodeficiency Virus Type 1 (HIV-1)
10%
Dolutegravir
8%
Bictegravir
8%
Long-acting Formulation
8%
Rifampin
8%
Drug Concentration
7%
Lymph Node
7%
Treatment of HIV Infection
6%
Rilpivirine
6%
Tuberculosis Regimen
6%
Tissue Pharmacokinetics
6%
Tuberculosis
6%
People Living with HIV (PLHIV)
6%
Prodrug
6%
RPP30
6%
Blood-brain Barrier
6%
Elvitegravir
5%
Rifamycin Antibiotics
5%
Tenofovir Diphosphate
5%
Central Nervous System
5%
Pharmacokinetic Simulation
5%
Astrocytes
5%
Levonorgestrel
5%
Renal Function Decline
5%
Osteoblast Lineage Cells
5%
Adipose Tissue
5%
Gender-affirming Hormone Therapy
5%
Polyplexes
5%
Human Immunodeficiency virus-1 Infection
5%
Latent Tuberculous Infection
5%
Rifabutin
5%
Strategy Study
5%
Third-line Antiretroviral Therapy
5%
LC-Mass
5%
Fixed-dose Combination
5%